| Amy Catherine Koglin, LMFT, BCBA | |
|
1020 Kabel Ave, Rhinelander, WI 54501-3918 | |
| (715) 361-2805 | |
| Not Available |
| Full Name | Amy Catherine Koglin |
|---|---|
| Gender | Female |
| Speciality | Behavior Analyst |
| Location | 1020 Kabel Ave, Rhinelander, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013209279 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | 956-124 (Wisconsin) | Secondary |
| 103K00000X | Behavior Analyst | 264-140 (Wisconsin) | Primary |
| Entity Name | Aspirus Rhinelander & Tomahawk Hospitals & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144991340 PECOS PAC ID: 9335059856 Enrollment ID: O20031126000706 |
News Archive
At a time when American military forces are stretched thin overseas, a growing number of potential recruits are too fat to enlist, according to an analysis by Cornell University researchers.
Burns are one of the most common injuries suffered by Australians and one of the top causes of death in children under four. While survival rates for burns patients have improved substantially, treating paediatric burns remains challenging, especially with the rise of multi-drug resistant bacteria.
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Clinical trial results reveal that a medication used to treat Alzheimer's disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Catherine Koglin, LMFT, BCBA 1010 River Reserve Dr, Hartland, WI 53029-2911 Ph: (262) 893-8401 | Amy Catherine Koglin, LMFT, BCBA 1020 Kabel Ave, Rhinelander, WI 54501-3918 Ph: (715) 361-2805 |
News Archive
At a time when American military forces are stretched thin overseas, a growing number of potential recruits are too fat to enlist, according to an analysis by Cornell University researchers.
Burns are one of the most common injuries suffered by Australians and one of the top causes of death in children under four. While survival rates for burns patients have improved substantially, treating paediatric burns remains challenging, especially with the rise of multi-drug resistant bacteria.
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Clinical trial results reveal that a medication used to treat Alzheimer's disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.
› Verified 7 days ago